Sickle Cell Disease Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Disease Indication (Sickle Cell Anemia, Sickle Hemoglobin-C Disease, Sickle Beta-Plus Thalassemia, Sickle Hemoglobin-D Disease, Sickle Hemoglobin-O Disease and Others), Type of Treatment (Blood Transfusion, Pharmacotherapy (Hydroxyurea, and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)), Gene Therapy (Casgevy, Lyfgenia) and Other Treatment), Type of Diagnosis, Route of Administration (Oral and Parenteral), Age Group (Adults, Pediatrics and Geriatrics), Type of Drug Class, Type of Complication, Distribution Channels, End User, Geographical Regions and Leading Players